L

LSL Pharma Group Inc
XTSX:LSL

Watchlist Manager
LSL Pharma Group Inc
XTSX:LSL
Watchlist
Price: 0.405 CAD -1.22%
Market Cap: CA$51.3m

LSL Pharma Group Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

LSL Pharma Group Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
L
LSL Pharma Group Inc
XTSX:LSL
Inventory
CA$9.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Inventory
$1.6B
CAGR 3-Years
14%
CAGR 5-Years
8%
CAGR 10-Years
3%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Inventory
CA$135.9m
CAGR 3-Years
14%
CAGR 5-Years
19%
CAGR 10-Years
57%
Spectral Medical Inc
TSX:EDT
Inventory
CA$377k
CAGR 3-Years
4%
CAGR 5-Years
1%
CAGR 10-Years
5%
Cipher Pharmaceuticals Inc
TSX:CPH
Inventory
$6.7m
CAGR 3-Years
43%
CAGR 5-Years
49%
CAGR 10-Years
20%
No Stocks Found

LSL Pharma Group Inc
Glance View

Market Cap
51.3m CAD
Industry
N/A

LSL Pharma Group, Inc. operates as a pharmaceutical company. The company is headquartered in Boucherville, Quebec. The company went IPO on 2011-03-08. The firm specializes in the development, manufacturing, and distribution of natural health products and dietary supplements in solid dosage forms. The firm is also engaged in selling sterile ophthalmic pharmaceutical products.

LSL Intrinsic Value
0.446 CAD
Undervaluation 9%
Intrinsic Value
Price CA$0.405
L

See Also

What is LSL Pharma Group Inc's Inventory?
Inventory
9.1m CAD

Based on the financial report for Dec 31, 2024, LSL Pharma Group Inc's Inventory amounts to 9.1m CAD.

What is LSL Pharma Group Inc's Inventory growth rate?
Inventory CAGR 1Y
122%

Over the last year, the Inventory growth was 122%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett